EUR/USD 1.18550
-0.099%
Gold 3681.20
-0.234%
Oil 64.034
-0.210%
USD/JPY 146.518
0.048%
GBP/USD 1.36425
-0.016%
GBP/JPY 199.893
0.039%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
Baidu (09888.HK) rose more than 15% during the day, with a turnover exceeding HK$3.2 billion.On September 17, Hong Kong Chief Executive John Lee delivered a new policy address at the Legislative Council of the Hong Kong Special Administrative Region. John Lee announced the establishment of a Northern Metropolis Development Committee, which he will lead.According to futures data on September 17, overnight shibor was 1.4830%, up 4.60 basis points; 7-day shibor was 1.5190%, up 4.40 basis points; 14-day shibor was 1.6070%, up 10.10 basis points; January shibor was 1.5410%, up 0.60 basis points; March shibor was 1.5540%, up 0.10 basis points.Tesla Inc (TSLA.O) has settled a lawsuit related to its Autopilot software following a fatal 2019 crash in Gardner, California, court documents show.On September 17th, a new report from the Financial Markets and Economic Research Team of Sumitomo Mitsui Securities indicated that the Bank of Japan may signal an October interest rate hike at this weeks meeting. The team believes that while the likelihood of adjusting the policy rate at this meeting is low, the central bank may guide market expectations of a rate hike through policy communications. The team also emphasized that it is closely monitoring the depreciation pressure on the yen from US policy developments. The report added that press conferences by candidates for the Liberal Democratic Party presidential election are also worth watching. If the candidates signal future fiscal expansion, this could further steepen the Japanese government bond yield curve.

AstraZeneca's nasal spray vaccine trial for COVID experiences a setback

Charlie Brooks

Oct 11, 2022 11:23

16.png


Tuesday, attempts by researchers from Oxford University and AstraZeneca (NASDAQ:AZN) Plc to manufacture a nasal-spray version of their jointly developed COVID-19 injection were hindered by the failure of first human tests to give the required degree of protection.


During the first of generally three phases of clinical testing, a minority of trial participants had an antibody response in their respiratory mucous membranes, according to a statement released by the University of Oxford on Tuesday.


In addition, the immune response measured in the blood was weaker than that caused by an arm injection.


Researchers from throughout the world have high hopes for nasal spray vaccinations against the coronavirus, as it is predicted that the method could prevent infection and illness by stimulating an immune response directly in the airways, where the virus enters the body.


In addition, the method would be less painful and easier to administer than injections.


In India and China, regulators have previously authorized the administration of drugs via the airways.


Last month, India's health minister approved Bharat Biotech's COVID-19 nasal spray vaccine, while China's medicines regulator approved CanSino Biologics Inc's COVID-19 inhaled vaccine on an emergency basis.


CanSino has said that its nebuliser-delivered vaccine can develop robust immunity to successfully restrict disease, but Bharat's trial findings are not yet available.


The British study included 30 unvaccinated patients and 12 volunteers who had previously undergone a normal two-dose immunization course.


In this study, the nasal spray did not perform as well as anticipated, according to Sandy Douglas, the trial's primary investigator at the Jenner Institute of Oxford University.


She went on to say, "We believe that delivery of vaccinations through the nose and lungs remains a viable option, but this study suggests that there will be challenges in making nasal sprays a reliable alternative."


During the AstraZeneca-funded trial, no severe adverse events or safety concerns were reported, according to the release.

Suggestion